Terumo BCT's Localized Production in China Ushers in a New Era of High-Quality Healthcare

Terumo BCT's Localized Production in China Ushers in a New Era of High-Quality Healthcare"China is a crucial strategic market for Terumo BCT, and indeed for the entire Terumo Group," stated Antona Gawen, President and CEO of Terumo BCT, at the recent launch ceremony for its domestic manufacturing operations. This ceremony marked the official entry of Terumo BCT, a global leader in blood separation technology, into localized production in China

Terumo BCT's Localized Production in China Ushers in a New Era of High-Quality Healthcare

"China is a crucial strategic market for Terumo BCT, and indeed for the entire Terumo Group," stated Antona Gawen, President and CEO of Terumo BCT, at the recent launch ceremony for its domestic manufacturing operations. This ceremony marked the official entry of Terumo BCT, a global leader in blood separation technology, into localized production in China. This move aims to provide the Chinese market with higher-quality domestically manufactured medical products and contribute to the advancement of China's healthcare industry.

At the launch ceremony, Terumo BCT announced that its initial domestically produced products include the TRIMA ACCEL blood component separation system and its associated tubing, as well as the Spectra Optia blood separation system and its associated tubing. To achieve this localization goal, the company plans to invest approximately RMB 100 million (USD 15 million) in the Chinese market. This substantial investment will not only boost the local economy but also accelerate innovation and technological advancements in research and manufacturing, injecting new vitality into China's healthcare sector.

Gawen emphasized that Terumo Medical Products (Hangzhou) Co., Ltd., one of Terumo's largest manufacturing bases, possesses a stable and efficient supply chain, ensuring the provision of high-quality medical products to the Chinese market. She pointed out that the company's focus is not on short-term fluctuations but on long-term returns. While the initial investment is significant, it will have profound implications for the company's localized development in the long run. Introducing advanced technologies into domestic production allows for faster responsiveness to Chinese customer needs, significantly improving treatment outcomes for Chinese patients and ultimately contributing to their healthier future.

Terumo BCT has cultivated the Chinese market for over three decades. Since entering the market in the 1990s, the company has installed nearly 4,000 units in China, serving over a thousand clients nationwide, with its business continuously expanding. The equipment introduced for domestic production are established flagship products of Terumo BCT, proven reliable and stable through years of market testing.

Regarding the specific performance of the localized equipment, Gawen explicitly stated that Terumo BCT's domestically produced products in China will maintain the same global quality standards. Terumo is committed to bringing its best products to China. In the future, Terumo BCT will continue to deepen its localization strategy, strengthen collaboration with local partners, and contribute its wisdom and strength to the advancement of China's healthcare industry and the building of a healthier and better society.

Gawen specifically highlighted that the products now being manufactured locally in China have been globally sold for 22 years; this localization simply represents a change in production location. The company has no intention of reducing the configuration of domestically produced products in China, as this would contradict both customer and company values. This commitment to consistent global quality standards reflects Terumo BCT's dedication to the Chinese market and its responsibility to Chinese patients.

Commenting on her understanding of industry changes, Gawen believes that the Chinese government's active promotion of industrial transformation driven by new productivity is creating new opportunities for Terumo BCT's development. Terumo BCT will continue to advance its localization initiatives, leveraging its product technology advancements to support industrial innovation and efficiency improvements, and contributing to China's medical cause.

Looking ahead, Terumo BCT plans to further deepen its localization process, with a key focus on in-depth collaboration with local clinicians and researchers. Through close cooperation with Chinese medical professionals, Terumo BCT can better understand the needs of the Chinese market and develop and improve products to meet the specific medical needs of Chinese patients. This collaborative model will accelerate the localization process and promote innovation and progress in medical technology.

Terumo BCT's localized production in China is not merely an investment but a long-term commitment to the development of the Chinese healthcare market. By introducing advanced blood separation technology and advanced manufacturing equipment, Terumo BCT will support the modernization of China's healthcare industry, improve healthcare services, and ultimately benefit millions of Chinese patients. This substantial investment will yield long-term economic and social benefits, propelling China's healthcare sector to new heights. Terumo BCT's long-term commitment to the Chinese market and its adherence to high-quality products will have a positive and far-reaching impact on the development of China's healthcare industry. This reflects not only Terumo BCT's own development strategy but also its contribution and social responsibility to China's healthcare cause. Through its continued localization strategy, Terumo BCT will work hand-in-hand with the Chinese medical community to contribute to the creation of a healthy China.

Terumo BCT's commitment to the Chinese market is evident not only in its substantial investment and implementation of localized production, but also in its strict control over product quality and continuous investment in technological innovation. The company will continue to deepen its localization strategy, actively participating in the reform and development of China's healthcare industry, providing Chinese patients with higher-quality medical services, and contributing to the creation of a healthy China. This will be an important component of Terumo BCT's long-term development strategy, a crucial measure for its deep cultivation of the Chinese market and the achievement of sustainable development. Through close cooperation with Chinese medical institutions and professionals, Terumo BCT will continuously improve its products and services to meet the ever-changing demands of the Chinese market and make even greater contributions to the progress of China's healthcare cause. This will be the cornerstone of Terumo BCT's long-term development in the Chinese market and an important embodiment of its social responsibility.

Terumo BCT's localized production strategy has not only brought high-quality medical products to Chinese patients, but has also injected new vitality into China's healthcare industry, promoting technological innovation and industrial upgrading. This will have a profound impact on the development of China's medical technology and the improvement of healthcare service levels, ultimately benefiting the vast majority of the Chinese people. Terumo BCT will continue to be committed to working with its Chinese partners for joint development, working together to build a healthy China, and making continuous contributions to China's medical cause. This is not only Terumo BCT's corporate responsibility but also an important part of its long-term development strategy. By continuously deepening its localization strategy, Terumo BCT will work closely with the Chinese medical community to jointly promote the development of China's healthcare cause and contribute to the construction of a healthy China. This will be a long and continuous process, and Terumo BCT will always adhere to its commitment to the Chinese market and will make unremitting efforts for it.

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])